Ticker

PVLA

Palvella Therapeutics, Inc.

9 catalysts on file

PVLA

Palvella Therapeutics, Inc.

Phase 3 Confirmed

QTORIN™ rapamycin

microcystic lymphatic malformations

178d ago Feb 24, 2026

SEC 8-K verified 2mo ago

Countdown card →

PVLA

Palvella Therapeutics, Inc.

Phase 3 Confirmed

QTORIN 3.9% rapamycin anhydrous gel

microcystic lymphatic malformations

178d ago Feb 24, 2026

SEC 8-K verified 2mo ago

Countdown card →

PVLA

Palvella Therapeutics, Inc.

Phase 2 AI-extracted

QTORIN™ rapamycin

Clinically Significant Angiokeratomas

93d ago May 20, 2026

SEC 8-K verified 2mo ago

Countdown card →

PVLA

Palvella Therapeutics, Inc.

Catalyst AI-extracted

Undisclosed program

93d ago May 20, 2026

SEC 8-K verified 2mo ago

Countdown card →

PVLA

Palvella Therapeutics, Inc.

AdCom AI-extracted

QTORIN™ rapamycin

cutaneous venous malformations

52d ago ~ Jun 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

PVLA

Palvella Therapeutics, Inc.

Catalyst AI-extracted

QTORIN™ rapamycin

Microcystic Lymphatic Malformations

52d ago ~ Jun 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

PVLA

Palvella Therapeutics, Inc.

PDUFA AI-extracted

QTORIN™ rapamycin

microcystic lymphatic malformations

T-minus 132 days ~ Dec 31, 2026

SEC 8-K verified 2mo ago

Countdown card →

PVLA

Palvella Therapeutics, Inc.

Phase 2 AI-extracted

QTORIN™ pitavastatin

disseminated superficial actinic porokeratosis

T-minus 132 days ~ Dec 31, 2026

SEC 8-K verified 2mo ago

Countdown card →

PVLA

Palvella Therapeutics, Inc.

Approval AI-extracted

QTORIN™ rapamycin

microcystic lymphatic malformations

T-minus 313 days ~ Jun 30, 2027

SEC 8-K verified 2mo ago

Countdown card →